Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | NPEPPS | P55786 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748698 | 1.00 | LMNA (0.50) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748702 | 0.90 | LMNA (0.44) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748691 | 0.85 | LMNA (0.46) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748756 | 0.84 | LMNA (0.44) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748752 | 0.84 | LMNA (0.44) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748701 | 0.83 | LMNA (0.38) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL25748747 | 0.80 | LMNA (0.48) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL19762768 | 0.79 | ADORA1 (0.49) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL18937381 | 0.79 | ADORA1 (0.49) | LMNAADORA2AADORA2BSLC29A1CYP1A2 | |
| SCHEMBL20692151 | 0.79 | ADORA1 (0.49) | LMNAADORA2AADORA2BSLC29A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691990-B2 | Salts of compounds and crystals thereof | EISAI R&D MANAGEMENT CO., LTD (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11339188-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | LMNA 2684/4885ADORA2A 3844/4885ADORA2B 4297/4885 |
| US-11339188-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | LMNA 2684/4885ADORA2A 3844/4885ADORA2B 4297/4885 |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | LMNA 2684/4885ADORA2A 3844/4885ADORA2B 4297/4885 |
| US-11691990-B2 | Salts of compounds and crystals thereof | SCN5A, SFN, GPR35 | LMNA 3451/4885ADORA2A 154/4885ADORA2B 607/4885 |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | NME4, NME2, DPYD | LMNA 2561/4885ADORA2A 314/4885ADORA2B 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.